October 29, 2024 05:33 PM EDT

Sage, Biogen won't pursue major depression approval for postpartum pill

Max Gelman

Senior Editor

It’s official: Sage and Biogen will not attempt to get their postpartum depression pill Zurzuvae approved in the broader population of people with major depressive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage, Biogen won't pursue major depression approval for postpartum pill

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer's drug

Sage, Bio­gen won't pur­sue ma­jor de­pres­sion ap­proval for post­par­tum pill

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Sage, Biogen won't pursue major depression approval for postpartum pill